Nvidia (NVDA) remains a top growth investment following record earnings, with management guiding for 70% revenue growth next fiscal year on sustained AI infrastructure demand. Salesforce (CRM) presents an attractive enterprise software opportunity after raising full-year revenue guidance to $46 billion and securing its position as a core data layer for AI agents. In healthcare, Moderna (MRNA) offers high-upside potential in the emerging personalized cancer immunotherapy market following breakthrough trial results for its custom mRNA melanoma treatment. Conversely, investors should exercise caution with long-duration fixed income, as a massive $10 trillion government debt refinancing cycle over the next 12 months threatens to keep 30-year U.S. Treasury yields elevated above their current 5.2% to 5.3% range.

Nvidia (NVDA)

• Nvidia delivered record quarterly results, reporting $96.2 billion in revenue (up 106% year-over-year) and $60 billion in net profit with 75% gross margins.
• Forward guidance came in well ahead of Wall Street projections, with the company guiding for 70% growth next fiscal year versus consensus expectations of 45%, while noting performance remains supply-constrained.
• The company continues to build out a full-stack ecosystem through reported strategic acquisitions, including Hugging Face ($12 billion) and Poolside ($6 billion), aiming to secure the open-source developer and distribution layer.
• Nvidia is expanding vertically from hardware into cloud hosting (Neo-cloud), custom models, and APIs to offset competition from customer-developed in-house silicon.

Takeaways

• AI capital expenditure trends remain strong, indicating sustained multi-year hardware demand rather than a near-term bubble.
• Expanding into open-source platforms and cloud infrastructure creates a resilient ecosystem moat around its core GPU sales.
• Key risks include long-term competition from hyperscalers developing proprietary chips and alternative semiconductor architectures.

Salesforce (CRM)

• Salesforce shares gained over 20% after posting quarterly revenue of $11.3 billion (up 11% year-over-year) and beating adjusted EPS expectations with $5.90 versus $3.27 expected.
• Management raised full-year revenue guidance to $46 billion, driven by strong net dollar retention and stabilization in enterprise software spending.
• The company is positioning itself as a core infrastructure layer for AI through its partnership with Anthropic, allowing AI models like Claude to serve as front-end user interfaces that directly read from and write to Salesforce data.
• The platform's enterprise durability highlights a divergence between "horizontal systems of record" (which hold canonical data) and "vertical SaaS" (which primarily manage basic workflows vulnerable to automation).

Takeaways

• Large horizontal software providers that act as authoritative corporate systems of record are well-positioned to benefit from AI agents rather than be replaced by them.
• Look for enterprise SaaS companies that open their APIs to external AI agent frameworks to unlock previously unused platform features.
• Pure workflow and niche vertical SaaS applications face heightened disruption risk from custom, AI-generated internal software.

Moderna (MRNA)

• Moderna saw its market capitalization surge from approximately $20 billion to $60 billion following positive clinical trial readouts for its mRNA-based neoantigen cancer immunotherapy.
• The therapy utilizes tumor DNA sequencing to design custom mRNA sequences that train the patient's immune system to identify and destroy specific cancer cells, notably in melanoma.
• The company reportedly plans to price the personalized therapy at approximately $500,000 per patient, despite relatively low underlying manufacturing and sequencing costs.

Takeaways

• Personalized mRNA and neoantigen therapies represent a high-growth therapeutic category with strong clinical efficacy in early trials.
• Long-term valuation may face pressure from regulatory scrutiny over pricing, potential patent challenges, and lower-cost international or non-mRNA alternative delivery methods.

U.S. Treasuries & Long-Duration Fixed Income

• The 30-year U.S. Treasury yield reached a 19-year high between 5.2% and 5.3%, with short-term one-month yields hovering around 3.8% to 4.0%.
• In response, the Treasury Department increased long-dated bond buybacks from $2 billion to $4 billion in an effort to suppress yields ahead of massive borrowing needs.
• The federal government faces a significant refinancing cycle, with $10 trillion in debt maturing over the next 12 months that must be reissued at higher prevailing rates compared to the current average debt servicing cost of 3.4%.
• Prolonged high yields continue to spill over into the consumer economy, keeping average 30-year fixed mortgage rates elevated near 6.7% to 7.0%.

Takeaways

• High debt refinancing volume creates sustained upward pressure on long-term bond yields unless government spending deficits narrow substantially.
• Fixed income and interest-rate-sensitive assets face headwinds as higher borrowing costs ripple into housing affordability and corporate financing.
• If long-term yields approach the 6.0% threshold, expect increased fiscal strain and broader market volatility.